Carelon's Genetic Testing for Inherited Conditions Guideline: What Labs Must Document
Short answer: Carelon's guideline "Genetic Testing for Inherited Conditions" took effect September 19, 2026. It covers cardiac, mitochondrial, neurologic, retinal, and thrombophilia testing, preimplantation testing, and transplant rejection biomarkers. Tests not specifically mentioned are considered not medically necessary, so documentation of family history, panel focus, and management impact largely determines payment.
What does the Carelon guideline cover?
Carelon Medical Benefits Management publishes clinical appropriateness guidelines that health plans use to review genetic testing requests. The inherited-conditions guideline carries the document ID GEN06-0926.1-UC1026, lists an effective date of 09/19/2026, an "updated codes" status of 10/01/2026, and a last review date of 01/29/2026. The published text reviewed for this article does not include an itemized list of changes from the prior version, so labs should compare it against the version they have been working from rather than assume what moved.
The scope is testing of people who have symptoms of a suspected inherited condition or who may be at increased risk based on family history or ancestry. It spans hereditary cardiac, primary mitochondrial, neurologic, retinal, and thrombophilia testing, plus preimplantation genetic testing and transplant rejection biomarker testing. Other modalities, including chromosomal microarray, exome and genome sequencing, carrier screening, hereditary cancer, and somatic tumor testing, are addressed in separate Carelon guidelines. That split matters operationally: one patient's workup can touch several guidelines, each with its own criteria.
What general criteria apply to every request?
The guideline opens with general requirements that apply before any condition-specific rule. Testing must be medically necessary under all of several conditions, which include a suspected or significant presymptomatic risk, well-defined genes with high-sensitivity tests, established validity, no adequate alternative test, significant disease morbidity, and an expected effect on patient management. Germline testing is generally limited to once per lifetime per gene unless the person was previously inadequately tested.
For multigene panels, the guideline expects panels to be as focused as reasonably possible, with each gene associated with the condition under evaluation. Panel testing is not considered medically necessary when exome or genome sequencing is being performed or has already been performed. For a lab, that means a broad panel ordered for a narrow clinical question is a denial risk even when every gene on it is valid. Our genetic testing denials guide covers how medical necessity denials typically unfold and how appeals are built.
Which condition-specific rules should labs know?
Cardiac testing criteria address arrhythmia, cardiomyopathy, aortopathy, unexplained sudden cardiac death, and TTR sequencing for confirmed transthyretin amyloidosis. Mitochondrial testing follows a defined order, and the criteria describe a targeted nuclear gene panel of fewer than 30 genes. Neurologic criteria include SOD1 testing for adults with ALS who are candidates for tofersen. Retinal testing is medically necessary for a known familial variant; the rationale notes 339 genes linked to inherited retinal disorders as of November 2025, which illustrates why a broad retinal panel is hard to justify without a specific question.
Thrombophilia criteria cover Factor V Leiden and prothrombin G20210A and tie them to venous thromboembolism history, with thresholds such as VTE before age 50, a first-degree relative with VTE at or before age 40, and postpartum testing up to six weeks after delivery. If your lab serves Medicare patients as well, read this alongside our review of the MolDX hereditary thrombophilia LCD; the two policies do not have to match, and a lab may need separate order logic for each payer.
Age thresholds appear elsewhere too. The sudden cardiac death criterion refers to a decedent at or before age 50, and the aortic criterion refers to an event before age 60. These are the kind of facts a reviewer looks for first. If the requisition stores age as free text, they are easy to miss.
What does the guideline say is not medically necessary?
The guideline lists general population screening, universal prenatal testing, and MTHFR testing for thrombophilia risk as not medically necessary. It also states that genetic tests not specifically mentioned in the guideline are considered not medically necessary. That catch-all sentence is the most consequential line for new or niche assays: if a test is not named, the lab should not expect approval on general reasoning alone and should plan for an exception or appeal pathway, or for patient financial counseling before collection.
What counseling, accreditation and documentation does it expect?
Genetic counseling is strongly recommended before testing and should cover family and medical history, inheritance, test limitations, and the possibility of variants of uncertain significance. Post-test counseling is expected for any diagnostic result. Testing must be performed in a CLIA-certified laboratory, and results used for management should also come from a CAP-accredited laboratory. Clinical documentation must accurately reflect the patient's situation and the ordering provider's intent, and family history should be documented across first-, second-, or third-degree relatives as applicable to the inheritance pattern.
Laboratories cannot supply clinical documentation themselves, but they can make it easy for ordering clinicians to provide it. Requisition forms with required fields for relationship, age at diagnosis, prior testing, and the intended management decision reduce the back-and-forth that delays claims. Our guide to NCCN hereditary cancer testing guidelines shows the same pattern on the oncology side.
How should revenue cycle teams respond?
Start with a menu audit. Map each orderable test to the Carelon guideline that governs it, and flag orderables that straddle guidelines, such as a cardiomyopathy panel ordered after an exome. Next, check repeat-testing logic. The once-per-lifetime-per-gene principle means a prior result from another lab can block a new request, and duplicate claims can fail on other edits as well, as described in our guide to duplicate lab test denials and modifier 91. Where a prior negative result was limited in scope, document why the earlier testing was inadequate; our piece on retesting after negative panels discusses that argument for oncology panels.
Then track outcomes. Record denial reasons by guideline section for a quarter, so your appeal effort goes where denials actually cluster. Because the guideline text is proprietary and each health plan applies it under its own contract, confirm with the specific plan whether and how this version is in force for a given member. For order-time criteria checks across payers, see how ScreenMyGene supports lab and clinician workflows.
Frequently asked questions
When did the Carelon inherited conditions guideline take effect?
The guideline shows an effective date of September 19, 2026, with an updated-codes status dated October 1, 2026. Its last review date is listed as January 29, 2026. Health plans may adopt guidelines on their own schedules, so confirm the applicable plan's effective date for each member.
Which tests does the guideline address?
It addresses single-gene and multigene testing for hereditary cardiac, primary mitochondrial, neurologic, retinal, and thrombophilia conditions, plus preimplantation genetic testing and transplant rejection biomarkers. Exome and genome sequencing, microarray, carrier screening, hereditary cancer, and somatic tumor testing fall under separate Carelon guidelines.
Can a lab bill multigene panels after exome sequencing?
The guideline says panel testing is not medically necessary when exome or genome sequencing is being or has been performed. Labs should expect denials for that sequence of orders unless a plan allows an exception, and should document the clinical reason if one applies.
Is genetic counseling required before testing?
The guideline describes pre-test counseling as strongly recommended rather than universally required, and expects post-test counseling for any diagnostic result. Plans may apply stricter rules, so labs should check each plan's policy and keep counseling documentation with the order.
What happens if a test is not listed in the guideline?
The guideline states that genetic tests not specifically mentioned are considered not medically necessary. Labs should plan for denial, prepare an exception or appeal with supporting evidence, and counsel patients about possible out-of-pocket cost before collecting a specimen.
This article is for educational purposes only and does not constitute legal, billing, coding, or clinical advice. It summarizes a publicly posted payer guideline in our own words as of October 28, 2026; the guideline is proprietary to Carelon, and criteria vary by health plan. Verify requirements with the applicable plan and your compliance counsel.
Sources: Carelon Medical Benefits Management, Clinical Appropriateness Guideline "Genetic Testing for Inherited Conditions," Doc ID GEN06-0926.1-UC1026, effective 09/19/2026 (guidelines.carelonmedicalbenefitsmanagement.com).